Young person and adult screening KPI data: Q2 summary factsheets (1 July to 30 September 2024)
Updated 20 March 2025
Applies to England
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/nhs-population-screening-kpi-report-1-july-to-30-september-2024/young-person-and-adult-screening-kpi-data-q2-summary-factsheets-1-july-to-30-september-2024
This report should be read in conjunction with the full KPI data tables published each quarter.
Please note that the data presented for previous time periods may be impacted by the COVID-19 pandemic. As a result, time series trends should be interpreted with caution.
1. Abdominal aortic aneurysm screening
1.1 KPI AA2: Coverage: initial screen
AA2 (standard code AAA-S04) shows the proportion of eligible men who are tested. National performance of AA2 (see standard AAA-S04) in quarter 2 2024 to 2025 was 46.1%.
| Threshold | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Acceptable Threshold | ≤ 18.0% | ≤ 38.0% | ≤ 56.0% | ≤ 75.0% |
| Achievable Threshold | ≤ 21.0% | ≤ 42.0% | ≤ 64.0% | ≤ 85.0% |
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 156,922 | 340,697 | 46.1% |
| Region | Performance % |
|---|---|
| East of England | 48.2% |
| London | 37.2% |
| Midlands | 49.5% |
| North East and Yorkshire | 37.4% |
| North West | 49.2% |
| South East | 48.4% |
| South West | 55.0% |
| England | 46.1% |
1.2 KPI AA3: Coverage: annual surveillance screen
AA3 (standard code AAA-S05) shows the proportion of annual surveillance appointments due where there is a conclusive scan within 6 weeks either side of the due date. National performance of AA3 (see standard AAA-S05) in quarter 2 2024 to 2025 was 93.4%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 3,483 | 3,731 | 93.4% |
| Region | Performance % |
|---|---|
| East of England | 95.4% |
| London | 91.3% |
| Midlands | 94.1% |
| North East and Yorkshire | 93.3% |
| North West | 93.0% |
| South East | 89.6% |
| South West | 95.3% |
| England | 93.4% |
1.3 KPI AA4: Coverage: quarterly surveillance screen
AA4 (standard code AAA-S06) shows the proportion of quarterly surveillance appointments due where there is a conclusive scan within 4 weeks either side of the due date. National performance of AA4 (see standard AAA-S06) in quarter 2 2024 to 2025 was 93.3%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 2,577 | 2,763 | 93.3% |
| Region | Performance % |
|---|---|
| East of England | 94.7% |
| London | 87.6% |
| Midlands | 92.2% |
| North East and Yorkshire | 96.4% |
| North West | 90.9% |
| South East | 93.1% |
| South West | 94.1% |
| England | 93.3% |
2. Diabetic eye screening
2.1 KPI DE1: Uptake: Routine digital screening
DE1 (standard code DES-S07) shows the proportion of those offered routine digital screening (RDS) who attend a RDS event where images are captured. DE1 is an annual rolling figure. National performance of DE1 in quarter 2 2024 to 2025 was 82.3%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 2,632,389 | 3,199,651 | 82.3% |
| Region | Performance % |
|---|---|
| East of England | 85.6% |
| London | 81.0% |
| Midlands | 78.8% |
| North East and Yorkshire | 82.2% |
| North West | 79.9% |
| South East | 85.6% |
| South West | 86.6% |
| England | 82.3% |
2.2 KPI DE2: Test: Timeliness of results letters
DE2 (standard code DES-S10) shows the proportion of eligible people with diabetes attending for diabetic eye screening, digital surveillance or slit lamp biomicroscopy surveillance to whom results were issued within 3 weeks after the screening event. National performance of DE2 in quarter 2 2024 to 2025 was 99.1%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 793,326 | 800,322 | 99.1% |
| Region | Performance % |
|---|---|
| East of England | 99.7% |
| London | 99.6% |
| Midlands | 99.6% |
| North East and Yorkshire | 99.4% |
| North West | 95.7% |
| South East | 99.8% |
| South West | 99.7% |
| England | 99.1% |
2.3 KPI DE3: Intervention/treatment: Timely consultation for people with diabetes who are screen positive
DE3 (standard code DES-S12) shows the proportion of individuals with an urgent referral who attend a first consultation in the hospital eye service within 6 weeks of their screening or surveillance event. National performance of DE3 in quarter 2 2024 to 2025 was 67.0%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 2,143 | 3,200 | 67.0% |
| Region | Performance % |
|---|---|
| East of England | 60.7% |
| London | 71.5% |
| Midlands | 67.9% |
| North East and Yorkshire | 75.6% |
| North West | 61.2% |
| South East | 64.9% |
| South West | 68.1% |
| England | 67.0% |
2.4 KPI DE4: Uptake: Repeat non-attenders
DE4 (standard code DES-S08) shows the proportion of eligible people with diabetes who have not attended for routine digital screening in the previous 3 years. National performance of DE4 in quarter 2 2024 to 2025 was 9.4%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 213,247 | 2,270,431 | 9.4% |
| Region | Performance % |
|---|---|
| East of England | 7.8% |
| London | 8.2% |
| Midlands | 11.6% |
| North East and Yorkshire | 9.8% |
| North West | 11.2% |
| South East | 7.9% |
| South West | 7.5% |
| England | 9.4% |
3. Bowel cancer screening
3.1 KPI BCS1: Uptake
BCS1 shows the proportion of invited people who were screened (adequately participated in FOBt bowel cancer screening), within the invited screening episode (at time of reporting). National performance of BCS1 (standard BCSP-S02) in quarter 2 2024 to 2025 was 63.4%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 1,259,150 | 1,985,148 | 63.4% |
| Region | Performance % |
|---|---|
| East of England | 67.3% |
| London | 51.7% |
| Midlands | 64.5% |
| North East and Yorkshire | 66.2% |
| North West | 61.7% |
| South East | 65.8% |
| South West | 68.2% |
| England | 63.4% |
3.2 KPI BCS2: Coverage
BCS2 (standard code BCSP-S01) shows the proportion of eligible people aged 60-74 who were screened (adequately participated in FOBt bowel cancer screening) in the 30 month period. National performance of BCS2 (standard BCSP-S01) in quarter 1 2024 to 2025 was 71.9%.
BCS2 is collected 6 months (2 quarters) in arrears.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 1 2024 to 2025 | 6,816,220 | 9,476,037 | 71.9% |
| Region | Performance % |
|---|---|
| East of England | 73.0% |
| London | 64.4% |
| Midlands | 71.5% |
| North East and Yorkshire | 73.8% |
| North West | 70.6% |
| South East | 74.3% |
| South West | 75.7% |
| England | 71.9% |
4. Breast screening
4.1 KPI BS1: Uptake
BS1 (standard code BSP-S03a) shows the proportion of eligible women who have a technically adequate screen within 6 months of date of first offered appointment. National performance of BS1 (standard BSP-S03) in quarter 2 2024 to 2025 was 66.1%.
Provisional quarterly data should be used with caution to measure performance as it will contain a proportion of women who were invited but have not yet attended the appointment. Data on this indicator will only be accurate 6 months after the end of the reporting period.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 469,057 | 709,619 | 66.1% |
| Region | Performance % |
|---|---|
| East of England | 69.0% |
| London | 59.1% |
| Midlands | 64.9% |
| North East and Yorkshire | 68.8% |
| North West | 68.8% |
| South East | 70.3% |
| South West | 62.0% |
| England | 66.1% |
4.2 KPI BS2: Uptake: Screening round length
BS2 (standard code BSP-S04a) shows the proportion of eligible women whose date of first offered appointment is within 36 months of their previous episode (routine programme). National performance of BS2 (standard BSP-S04) in quarter 2 2024 to 2025 was 93.4%.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2024 to 2025 | 460,521 | 492,898 | 93.4% |
| Region | Performance % |
|---|---|
| East of England | 84.6% |
| London | 98.4% |
| Midlands | 91.9% |
| North East and Yorkshire | 94.9% |
| North West | 95.1% |
| South East | 95.1% |
| South West | 92.2% |
| England | 93.4% |
5. Cervical screening
5.1 KPI CS1: Coverage under 50 years
CS1 (standard CSP-S01) shows the proportion of women in the resident population eligible for cervical screening aged 25 to 49 years at end of period reported who were screened adequately within the previous 3.5 years.
On the 24 June 2024, the NHS Cervical Screening Programme replaced the National Health Application and Infrastructure Services (NHAIS) call and recall IT system with the Cervical Screening Management System (CSMS).
Cervical screening coverage data from the CSMS is not yet available for reporting. Please see the Q1 KPI publication for the latest available position.
5.2 KPI CS2: Coverage 50 years and above
CS2 (standard CSP-S02)shows the proportion of women in the resident population eligible for cervical screening aged 50 to 64 years at end of period reported who were screened adequately within the previous 5.5 years.
On the 24 June 2024, the NHS Cervical Screening Programme replaced the National Health Application and Infrastructure Services (NHAIS) call and recall IT system with the Cervical Screening Management System (CSMS).
Cervical screening coverage data from the CSMS is not yet available for reporting. Please see the Q1 KPI publication for the latest available position.